Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines

Hematulin,Arunee; Sagan,Daniel; Sawanyawisuth,Kanlayanee; Seubwai,Wunchana; Wongkham,Sopit

doi:10.3892/ijo.2014.2520

Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines

Authors:
- Arunee Hematulin
- Daniel Sagan
- Kanlayanee Sawanyawisuth
- Wunchana Seubwai
- Sopit Wongkham
View Affiliations

Affiliations: Radiobiology Research Laboratory, Department of Radiation Technology, Faculty of Allied Health Science, Naresuan University, Phitsanulok 65000, Thailand, Independent Researcher, D-93051 Regensburg, Germany, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand, Department of Forensic Science, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Published online on: June 24, 2014 https://doi.org/10.3892/ijo.2014.2520
Pages: 1159-1166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma is a destructive malignancy with a poor prognosis and lack of effective medical treatment. Radiotherapy is an alternative treatment for patients with unresectable cholangiocarcinoma. However, there are limited data on the radiation responsiveness of individual cholangiocarcinoma cells, which is a key factor that influences radiation treatment outcome. In this study, we found that cholangiocarcinoma cell lines differ remarkably in their radiosensitivity. The variation of radiosensitivity of cholangiocarcinoma cells correlates with their p53 status and existing G1 and/or G2 checkpoint defects. We also demonstrated the potential of checkpoint kinase Chk1/2 inhibition on the enhancement of the radiosensitivity of cholangiocarcinoma cells. Thus, this study provides useful information for predicting radiation response and provides evidence for the enchantment of radiotherapeutic efficiency by targeting checkpoint kinase Chk1/2 in some subpopulations of cholangiocarcinoma patients.

View Figures

View References

1	Welzel TM, McGlynn KA, Hsing AW, O’Brien TR and Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 98:873–875. 2006. View Article : Google Scholar
2	Luke C, Price T and Roder D: Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pac J Cancer Prev. 11:1479–1485. 2010.PubMed/NCBI
3	Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P and Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
4	Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
5	Patel T: Cholangiocarcinoma - controversies and challenges. Nat Rev Gastroenterol Hepatol. 8:189–200. 2011. View Article : Google Scholar : PubMed/NCBI
6	Arrington AK, Nelson RA, Falor A, Luu C, et al: Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma. World J Gastrointest Surg. 5:178–186. 2013. View Article : Google Scholar : PubMed/NCBI
7	DeOliveira ML, Cunningham SC, Cameron JL, et al: Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 245:755–762. 2007.PubMed/NCBI
8	Hemming AW, Reed AI, Fujita S, Foley DP and Howard RJ: Surgical management of hilar cholangiocarcinoma. Ann Surg. 241:699–702. 2005. View Article : Google Scholar
9	Ramirez-Merino N, Aix SP and Cortes-Funes H: Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol. 5:171–176. 2013. View Article : Google Scholar
10	Zografos GN, Farfaras A, Zagouri F, Chrysikos D and Karaliotas K: Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int. 10:10–20. 2011. View Article : Google Scholar
11	Alberts SR, Al-Khatib H, Mahoney MR, et al: Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 103:111–118. 2005. View Article : Google Scholar
12	Patt YZ, Hassan MM, Aguayo A, et al: Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 101:578–586. 2004. View Article : Google Scholar : PubMed/NCBI
13	Woo SM, Lee WJ, Han SS, et al: Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Chemotherapy. 58:225–232. 2012. View Article : Google Scholar : PubMed/NCBI
14	Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M and Pawlik TM: Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 22:3929–3942. 2013. View Article : Google Scholar : PubMed/NCBI
15	Barney BM, Olivier KR, Miller RC and Haddock MG: Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 7:672012. View Article : Google Scholar
16	Gonzalez Gonzalez D, Gouma DJ, Rauws EA, van Gulik TM, Bosma A and Koedooder C: Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol. 10(Suppl 4): 215–220. 1999.PubMed/NCBI
17	Isayama H, Tsujino T, Nakai Y, et al: Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol. 18:2364–2370. 2012. View Article : Google Scholar : PubMed/NCBI
18	McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB and Curley SA: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 174:605–608. 1997. View Article : Google Scholar
19	Brunner TB and Eccles CL: Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol. 186:672–680. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ghafoori AP, Nelson JW, Willett CG, et al: Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 81:654–659. 2011. View Article : Google Scholar : PubMed/NCBI
21	Mladenov E, Magin S, Soni A and Iliakis G: DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 3:1132013. View Article : Google Scholar : PubMed/NCBI
22	Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 8:545–554. 2008. View Article : Google Scholar : PubMed/NCBI
23	Balcer-Kubiczek EK: Apoptosis in radiation therapy: a double-edged sword. Exp Oncol. 34:277–285. 2012.PubMed/NCBI
24	Shimura T: Acquired radioresistance of cancer and the AKT/GSK3beta/cyclin D1 overexpression cycle. J Radiat Res. 52:539–544. 2011. View Article : Google Scholar : PubMed/NCBI
25	Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
26	Schmitt CA: Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer. 3:286–295. 2003. View Article : Google Scholar : PubMed/NCBI
27	Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
28	Bucher N and Britten CD: G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 98:523–528. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ma Z, Yao G, Zhou B, Fan Y, Gao S and Feng X: The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol Med Rep. 6:897–903. 2012.PubMed/NCBI
31	Riesterer O, Matsumoto F and Wang L: A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs. 29:514–522. 2011. View Article : Google Scholar : PubMed/NCBI
32	Tandle AT, Kramp T, Kil WJ, et al: Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur J Cancer. 49:3020–3028. 2013. View Article : Google Scholar : PubMed/NCBI
33	Tang Y, Dai Y, Grant S and Dent P: Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biol Ther. 13:379–388. 2012. View Article : Google Scholar : PubMed/NCBI
34	Maruyama M, Kobayashi N, Westerman KA, et al: Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT. Transplantation. 77:446–451. 2004. View Article : Google Scholar : PubMed/NCBI
35	Hematulin A, Sagan D, Eckardt-Schupp F and Moertl S: NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade. Cell Signal. 20:2276–2285. 2008. View Article : Google Scholar : PubMed/NCBI
36	Morgan MA, Parsels LA, Zhao L, et al: Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70:4972–4981. 2010. View Article : Google Scholar : PubMed/NCBI
37	Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753. 2005. View Article : Google Scholar : PubMed/NCBI
38	Deodato F, Clemente G, Mattiucci GC, et al: Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys. 64:483–488. 2006. View Article : Google Scholar : PubMed/NCBI
39	Bonkhoff H: Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer. 2012:5932412012. View Article : Google Scholar : PubMed/NCBI
40	Coventry BJ and Ashdown ML: Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 4:137–149. 2012. View Article : Google Scholar
41	Fei P and El-Deiry WS: P53 and radiation responses. Oncogene. 22:5774–5783. 2003. View Article : Google Scholar : PubMed/NCBI
42	Mazzatti DJ, Lee YJ, Helt CE, O’Reilly MA and Keng PC: p53 modulates radiation sensitivity independent of p21 transcriptional activation. Am J Clin Oncol. 28:43–50. 2005. View Article : Google Scholar : PubMed/NCBI
43	Lu C and El-Deiry WS: Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis. 14:597–606. 2009. View Article : Google Scholar : PubMed/NCBI